SINGAPORE, Sept. 23, 2025 /PRNewswire/ — Blue Planet Environmental Solutions, a leading environmental services company, participated in the Asia PE-VC Summit 2025 held in Singapore from September 10 to 11. Organized by DealStreetAsia, a Singapore-headquartered media company known for its coverage of private equity, venture capital, and startup ecosystems, the summit convened Asia-Pacific’s leading investors, fund managers, entrepreneurs, and industry leaders. This year, the event highlighted climate tech innovation, including the session “The Upside: Climate tech innovators on building a sustainable venture.”

On September 11, Prashant Singh, Co-Founder and CEO of Blue Planet, joined this session to share the company’s journey of creating a technology-driven platform that integrates municipal solid waste, e-waste, plastics, hazardous waste, and biofuels into a unified circular economy model.

“Our sector is very capital-intensive, requiring significant investment. Over the last decade, transition financing has improved, but responsible capital deployment remains critical, especially for technologies that have demonstrated real, tangible benefits,” Singh said.

He also emphasized the importance of scaling proven solutions such as landfill mining and reclamation projects. “Many viewed these projects as too complex or expensive, but they are essential to addressing legacy waste challenges. The key is to make them investible and scalable through technology, partnerships, and supportive policy frameworks.”

Singh highlighted Blue Planet’s focus on measurable outcomes, including carbon reduction, land reclaimed, jobs created, and supply chain traceability. He stressed that patient, risk-aligned capital and progressive policies will be vital to transform successful pilots into citywide sustainable systems.

Blue Planet’s participation at the Asia PE-VC Summit 2025 reinforced its leadership in climate technology and its commitment to building scalable, sustainable ventures that drive circular economy solutions across Asia.

About Blue Planet Environmental Solutions
Blue Planet Environmental Solutions is a technology-driven environmental services company dedicated to transforming waste management into a scalable, transparent, and impact-driven industry. The company integrates diverse waste streams into unified systems, leverages technology to track and reduce environmental impact, and partners with governments, corporations, and startups to build solutions aligned with ESG principles. With a focus on circular economy models, Blue Planet is at the forefront of Asia’s transition toward sustainable and data-driven environmental solutions.
For more information, please visit: https://blueplanet.asia

About DealStreetAsia
DealStreetAsia™ is a Singapore-headquartered, subscription-driven media company covering private equity, venture capital, M&As, listings, and the business of startups across Asia. It provides data, intelligence, and insights to investors and tracks startups that are shaping one of the fastest-growing regions in the world. The company also delivers in-depth analysis and breaking stories on deals, funding trends, and emerging sectors, helping both regional and international investors make informed decisions.

For more information about DealStreetAsia and our work, please visit: https://www.dealstreetasia.com/

SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ — Myriad Genetics (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (Nasdaq: SOPH), an AI technology company transforming precision medicine, announced a strategic collaboration to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test. This partnership will leverage Myriad’s advanced laboratory capabilities in the U.S. to support global testing for clinical trials and SOPHiA GENETICS’ broad, decentralized network of more than 800 connected institutions in more than 70 countries for global test deployment.

“Serving patients and healthcare providers along the cancer care continuum is a strategic focus for Myriad Genetics,” said Sam Raha, President and CEO, Myriad Genetics. “We expect this collaboration with SOPHiA GENETICS to support the development and global commercialization of comprehensive CDx solutions for our BioPharma partners with the potential to positively impact patient lives, add an important product offering to the Myriad menu and support the growth of our CDx programs.”

SOPHiA GENETICS and Myriad will initially focus on the liquid biopsy application, MSK-ACCESS® powered with SOPHiA DDM™. Developed in collaboration with Memorial Sloan Kettering Cancer Center, MSK-ACCESS® powered with SOPHiA DDM™ is an innovative liquid biopsy test that detects actionable genomic alterations from a single blood draw using proprietary, state-of-the-art algorithms which analyze circulating tumor DNA (ctDNA). By developing the application into a CDx, more patients can gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale.

Myriad will pursue regulatory submissions in the U.S., and SOPHiA GENETICS will manage regulatory submissions outside of the U.S. Both companies will collaborate across development activities. This innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally.

“This collaboration represents a pivotal moment for the industry,” said Jurgi Camblong, Co-founder and CEO of SOPHiA GENETICS. “By combining the complementary strengths of a specialty lab leader and a global testing network, we are not only expanding access to innovative oncology testing but also laying the foundation for a new hybrid model in companion diagnostics. This collaboration will allow us to serve both clinical and pharmaceutical partners better, while accelerating the adoption of liquid biopsy solutions across key markets.”

SOPHiA GENETICS and Myriad will participate in a panel discussion at the World CB and CDx Summit in Boston and provide additional details on the collaboration.

About SOPHiA GENETICS  
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions.  For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn. 

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence. 

SOPHiA GENETICS Forward-Looking Statements: 
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. 

About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

Myriad Genetics Safe Harbor Statement 
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including the company’s expectation that the collaboration with SOPHiA GENETICS to support the development and commercialization of comprehensive CDx solutions for the company’s BioPharma partners, add an important product offering to its menu and support the growth of its CDx programs, that by developing the application into a CDx, more patients will gain access to the benefits of this high-quality tumor profiling test, advancing personalized healthcare at scale, and that this innovative, hybrid approach is expected to provide pharmaceutical partners with access to key regulated markets globally. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

NEW YORK, Sept. 23, 2025 /PRNewswire/ — The country’s space infrastructure is expanding rapidly, supported by commercial and private enterprises, as well as technological advancements in Artificial Intelligence (AI), analytics, quantum computing, and 6G research. These developments are tightly integrated with China’s ambitious plans to deliver next-generation connectivity solutions. According to global intelligence firm ABI Research, China’s Serviceable Addressable Market (SAM) for satellite D2C subscription services could reach 30 million users by 2030, driven by the launch of new major LEO networks.

“What we’re seeing are opportunities in China’s space sector across a wide range of areas, including domestic commercial expansion in private and state-backed constellations, business opportunities in downstream applications, multi-application communication networks, and partnerships in adjacent technology areas,” explains Rachel Kong, Research Analyst at ABI Research. “These opportunities are strongly supported by government policies, which are a key driver in ramping up investments and funding for national initiatives. Examples include the Space Silk Road Initiative, the New Infrastructure Policy, and the Space-Ground Integrated Information Network Plan. Currently, two mega constellations, Spacesail and Guowang, are launching satellites with the aim of building networks that could potentially include tens of thousands of satellites.”

Active satellites in orbit are expected to increase from over 17,000 in 2025 to over 48,000 by 2032, representing a Compound Annual Growth Rate (CAGR) of 17.6%. Over 35% of these satellites are anticipated to come from the ‘big three’ Chinese Low-Earth Orbit (LEO) networks, including Honghu-3, which has not launched any satellites in orbit yet. With support from national space networks anticipated in the future, China’s direct-to-cellular (smartphone) and direct-to-device (IoT) opportunities lie in its large existing base of smartphone users and proliferation of IoT devices. These value-added services will ensure users remain connected to the domestic network during outages and natural disasters while also providing coverage overseas when traveling or operating beyond China’s terrestrial coverage.

“While the Chinese market shows growth potential supported by emerging mega-constellations, commercial opportunities are expected to be dominated by local players such as Spacesail, China Satellite Network Group’s Guowang, and the upcoming Hongqing Technology’s Honghu-3, which are largely supported by China Aerospace Science and Technology Corporation (CASC) as the market remains largely closed to foreign space services due to ongoing national security and regulatory requirements,” said Kong. “As more private and commercial players emerge in the market, we’ll be expecting to see higher levels of investments, competition, and collaboration in the space sector.”  

These findings are from ABI Research’s China’s Space Market and NTN Frontier: Company Profiles & Market Insights report, part of the company’s Space Technologies and Innovation research service, which includes research, data, and ABI Insights.

About ABI Research

ABI Research is a global technology intelligence firm uniquely positioned at the intersection of technology solution providers and end-market companies. We serve as the bridge that seamlessly connects these two segments by providing exclusive research and expert guidance to drive successful technology implementations and deliver strategies proven to attract and retain customers.

ABI Research是一家全球性的技术情报公司，拥有得天独厚的优势，充当终端市场公司和技术解决方案提供商之间的桥梁，通过提供独家研究和专业性指导，推动成功的技术实施和提供经证明可吸引和留住客户的战略，无缝连接这两大主体。

For more information about ABI Research’s services, contact us at +1.516.624.2500 in the Americas, +44.203.326.0140 in Europe, +65.6592.0290 in Asia-Pacific, or visit www.abiresearch.com.

Contact Info: 

Global
Jason Scheer
Tel: +1.516.624.2558
pr@abiresearch.com

This group of women demonstrates the power of connection; they transform the everyday into something more beautiful when together. By their sides: the versatile Duo bag, ever-present through life’s infinite possibilities.

NEW YORK, Sept. 23, 2025 /PRNewswire/ — Today, Kate Spade New York unveiled its Fall 2025 global brand campaign, “Spark Something Beautiful,” bringing back the iconic Gen Z “Duo” of four-time Grammy-nominated rapper Ice Spice and dancer and multi-faceted social media star Charli D’Amelio—and welcoming Grammy-winning singer-songwriter Laufey, and model Reign Judge. Firmly establishing the brand’s new chapter under CEO and Brand President Eva Erdmann, the campaign embraces a fresh aesthetic and new vision designed to connect with the next generation, celebrating the magic that happens when we are together with friends.

Set against the bustling backdrop of New York City, we follow our protagonist as she navigates on her own…until she approaches a street crossing.  As her friends join her, their togetherness sparks a transformation of the crossing into a celebration of how even a small moment of connection can spark something beautiful. 

“At Kate Spade New York, we believe that the little moments shared together are what truly brighten life,” said Kaisy Mae O’Reilly, Senior Vice President of Marketing. “Like the Duo Bag, our campaign stars reflect uniqueness and versatility—yet shine brightest together. At its heart, this campaign is about how showing up for each other can transform even the simplest moments into something extraordinary.”

The campaign introduces Laufey, whose wit, charm, and artistry resonate deeply with Gen Z audiences, alongside returning campaign stars Ice Spice and Charli D’Amelio, and model Reign Judge. Though distinct in personality, together the group reflects the power of connection (and the versatility of Kate Spade New York’s newest hero, the Duo Bag). They each demonstrate the ability to transform the everyday into something extraordinary.

“Music has always been about connection for me—whether it’s with the audience at a concert or the people closest to me in my everyday life,” says Laufey. “What drew me to this Kate Spade New York campaign is how it captures the beauty of those small, shared moments. I love the idea that friendship can turn something as simple as crossing the street into something magical—that really resonates with how I see the world.”

“I’ve always admired Kate Spade New York for creating designs that feel bold, universal and chic all at once,” says Ice Spice. “Being part of this campaign felt natural because it’s about the people who bring joy to your life and make you feel good. For me, that’s my friends. It’s no secret that behind every successful woman is her girlfriends hyping her up in the group chat.”

“I’m so happy to be working with Kate Spade New York again,” says Charli D’Amelio. “This campaign celebrates togetherness, and that means a lot to me because my friends are truly my support system through everything. In the busiest moments of my career, they’re the ones who bring me back to myself and remind me what’s important. I love that Kate Spade New York is shining a light on the fact that life is better when we are together.”

At the heart of the Fall campaign is the Duo Bag—a multi-tasking essential designed for infinite possibilities. With four ways to wear it (as a shoulder bag, crossbody, clutch, or belt bag), Duo is as versatile as the women who carry it. The Fall/Holiday 2025 collection features Duo in eye-catching colorways—Cashew Milk, Black, Leopard Multi, Dried Thyme, Lime Slice, Cinder Grey, and Burnt Sage—alongside holiday-ready hues like Milk Glass, Red Jam, Leopard Haircalf, and Nightshade. Prices range from $298–$348, with new styles continuing to roll out throughout the season in stores and online.

The Fall 2025 collection will be available to shop beginning September 23, 2025, with new styles rolling out throughout the season in Kate Spade New York stores and online. The campaign will launch across Kate Spade New York’s channels beginning the same day and run through February 2026.

Campaign Images & Video:
KV Images: HERE
:30 Hero Video: HERE

Credits:
Director: Julien Vallée
Photographer: Daniel Arnold
Creative Strategy: Mandai Loop
Creative Agency: Marcel
Production House: Wanda
Post Production House: Chemistry
Music: Amy McKnight – Rise Up Let’s Go
Stylist: Leith Clark (Laufey & Reign Judge), Timothy Garcia (Ice Spice), Carlee Suzanne Barrow & Anabel Bentle (Charli D’Amelio)
Hair: Jenny Cho-Semple (Laufey), Araxi Lindsey (Reign Judge), Dionte Gray (Ice Spice), Laura Polko (Charli D’Amelio)
Makeup: Dana Delaney (Laufey and Reign Judge), Karina Orozco (Ice Spice), Akina Shimizu (Charli D’Amelio)
Nails: Yoko (Laufey and Reign Judge), Brittney Boyce (Charli D’Amelio)

kate spade new york Fall 2025 lookbook:
FLAT-LAY: HERE
ON MODEL: HERE

About Kate Spade New York:
Since its launch in 1993 with a collection of six essential handbags, Kate Spade New York has always stood for color, wit, optimism, and femininity. Today, it is a global lifestyle brand synonymous with joy, delivering seasonal collections of handbags, ready-to-wear, jewelry, footwear, gifts, home décor and more. Known for its rich heritage and unique brand DNA, Kate Spade New York offers a distinctive point of view and celebrates communities of women around the globe who live their perfectly imperfect lifestyles. Kate Spade New York is part of the Tapestry house of brands.  

Charli D’Amelio x Kate Spade New York Fall 2025 Campaign

Ice Spice x Kate Spade New York Fall 2025 Campaign

Laufey x Kate Spade New York Fall 2025 Campaign

Reign Judge and Laufey x Kate Spade New York Fall 2025 Campaign

Charli D’Amelio, Ice Spice and Laufey x Kate Spade New York Fall 2025 Campaign

Ice Spice x Kate Spade New York Fall 2025 Campaign

Kate Spade New York Fall 2025 Duo Assortment